Abstract: Novel ubiquitin specific protease 13 (USP13) inhibitors are provided, along with methods for their use. The USP13 inhibitors described herein are useful in treating and/or preventing USP13-related diseases, such as neurodegenerative diseases and cancer. Also provided are methods for inhibiting USP13 in a cell using the compounds and compositions described herein.

Abstract: Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a neurodevelop-mental disease, a myodegenerative disease, a prion disease, a lysosomal storage disease or cancer in a subject.

Abstract: Provided herein are methods of treating a lysosomal storage disorder (LSD) in a subject and methods of promoting lysosomal clearance in one or more cells of a subject.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: Provided herein are compositions and methods for treating or preventing a neurodegenerative disease, a myodegenerative disease, a prion disease or a lysosomal storage disease in a subject.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: A system and method dispense medication through a smart pill that holds at least one medication and a mobile device capable of communicating wirelessly with the smart pill. The mobile device includes a user interface for communicating with a patient and at least one application program that includes program instructions for measuring an aspect of a patient's physiology. A processor on the mobile device is configured to execute a program for monitoring and communicating with the smart pill, causing at least one of the applications to execute and test the patient, and on the basis of the outcome of the testing, issue a signal for timing and amount of medication release from the smart pill to the patient. The application programs may include a cognitive test, an eye test, a balance test, and a reaction test which may use the display, camera, speaker and microphone of the mobile device.

Abstract: Provided herein are methods of treating a lysosomal storage disorder (LSD) in a subject and methods of promoting lysosomal clearance in one or more cells of a subject.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease in a subject using an inhibitor of discoidin domain receptor (DDR) tyrosine kinase.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: Provided herein are methods of promoting parkin activity in a subject, comprising: selecting a subject with a disorder associated with decreased Parkin activity; and administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme.

Abstract: Provided herein are methods of treating or preventing a neurodegenerative disease, a myodegenerative disease or a prion disease in a subject comprising administering a tyrosine kinase inhibitor.

Abstract: Provided herein are methods of promoting parkin activity in a subject, comprising: selecting a subject with a disorder associated with decreased Parkin activity; and administering to the subject an effective amount of a composition that increases parkin activity, wherein the composition is an inhibitor of a deubiquitinating enzyme.